A new treatment for endometrial cancer has shown strong potential in a Phase 3 clinical trial. Drugmaker Merck announced that their investigational drug, sacituzumab tirumotecan (sac-TMT), achieved its primary goals of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer. The TroFuse-005 trial stands as a landmark study, being the first […]